Cetirizine and Famotidine for COVID-19

• Status: Withdrawn
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cetirizine and famotidine in reducing the duration of symptoms in patients with COVID-19. Secondary aims are to determine if cetirizine and famotidine decrease severity and duration of symptoms, incidence of hospitalizations, ICU admissions, and death.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Treatments: Cetirizine; Famotidine

Criteria

Inclusion Criteria:

• 18 years old and above

• positive COVID-19 test (antigen or PCR)

• symptomatic from COVID-19

• symptoms less than or equal to 7 days

Exclusion Criteria:

• already enrolled in another COVID-19 drug study

• chronically taking a H1-receptor antagonist or H2-receptor antagonist

• have taken H1-receptor antagonist or H2-receptor antagonist less than 72 hours from expressed interest in the study.

• history of an adverse reaction to H1 or H2-receptor antagonists

• severe liver disease

• severe renal disease

• taking steroids

• taking hydroxychloroquine and/or azithromycin

• already participating in a COVID-19 vaccine trial

• already received a COVID-19 vaccine

• symptoms greater than 7 days

• have had COVID-19 more than once